Human cell-based microphysiologil systems of the gastrointestinal tract (GI) have shown tremendous potential to improve and accelerate the drug development process. Such models have the capability of establishing an integrated profile of drug pharmacology, safety, and absorption/metabolism. Unlike animal models, cell-based intestinal systems reprise human intestinal physiology, have significant cost- and time advantages, and are amenable to drug screening and mechanism-of-action studies.
This presentation will focus on existing cell-based intestinal platforms and highlight several applications including modeling of intestinal drug bioavailability/metabolism, GI inflammatory diseases (such as ulcerative colitis/Crohn’s disease), and mechanistic studies of drug-induced toxicity. Additionally, the presentation will address several key challenges in the field including the need for standardization/improved quality control and establishing translatability to clinical outcomes in human subjects. Finally, several “models-in-development” will be discussed to highlight the future potential of human cell based intestinal models.
Learning Objectives:
Upon completion, participants will have an understanding of how intestinal models are being increasingly implemented in drug development.
Upon completion, participants will have an understanding of the effort to standardize MPS platforms to improve quality and reproducibility.
Upon completion, participants will have an understanding of next-generation MPS platforms that are currently in development.